Top Markets
Coin of the day
Scilex Holding Company Scilex Holding Company

Scilex Holding Company

SCLX
Pozycja w akcjach #25627
Scilex Holding Company is a biopharmaceutical enterprise that specializes in... Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Cena akcji
$5.61
Ostatnia synchronizacja: 2026-08-20
Kapitalizacja rynkowa
$47.65M
Zmiana (1 dzień)
-0.68%
Zmiana (1 rok)
-67.26%
Kraj
US
Handel Scilex Holding Company (SCLX)

Kategoria

Historia ceny akcji dla Scilex Holding Company (SCLX)
Najwyższa cena zamknięcia: $6.52 dnia 2026-08-01

Najniższa cena zamknięcia: $346.22 dnia 2021-03-01
Historia cen akcji firmy Scilex Holding Company od 2021 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) -26.12%
2025 -11.79%
2024 -61.32%
2023 -63.10%
2022 -63.74%
2021 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$1.25K 75.69%
US
$268.08 49.82%
US
$262.00 25.06%
US
$489.01 44.10%
CH
$149.16 73.28%
US